Kornimate/medical-research-clean huggingface dataset:
the effects of muscle energy techniques on pain and quality of life in young females with primary dysmenorrhea

Conditions: Primary Dysmenorrhea

Summary: this study will be a quasi experimental study in which females aged 18 - 30 years with primary dysmenorrhea will be recruited in single group. they will be given a total of 3 sessions of treatment during a period of one menstrual cycle (one week). before and after the introduction of intervention pain and quality of life of participants will be assessed.

primary dysmenorrhea is one of the most prevalent gynecological conditions which impacts the quality of life of young females.primary dysmenorrhea is defined as cramping like pain during menstruation cycle without the presence of any pelvic pathology it is associated with symptoms like headache,vomitting and irritability.the aim of our study is to determine the effects of muscle energy technique in young females with primary dysmenorrhea in terms of pain and quality of life.this study will be a quasi experimental study.it will be conducted at foundation university college of physical therapy.paticipants will complete walidd scale,nprs and whoqol at baseline and then after intervention.all participants will receive post isometric relaxation of global muscles of core commonly involved in primary dysmenorrhea(gluteus maximus,illiopsoas and piriformis).post isometric relaxation technique will be applied to all the participants with participants using 20% of their maximum voluntary contractio with held time of 6-10 seconds followed by 15 to 30 seconds stretch,rest time of 5 seconds between each repetitions and 3-5 repetions.there will be a total of 3 sessiond of treatment(1st on second day of menstruation,2nd on fourth day of menstruatio and 3rd on seventh day of menstruation)during a period of one week (one menstraul cycle).

Eligibility criteria:
inclusion criteria: * female aged 18 - 30 * primary dysmenorrhea * unmarried exclusion criteria: * not on any contraceptive medicine for treatment of pelvic pathology * secondary dysmenorrhea and other issues such as endometriosis, pelvic inflammatory disease, ovarian cyst
quercetin pk/pd study in healthy adults and patients with hypercoagulable states

Conditions: Healthy

Summary: the goal of this study is to evaluate how much quercetin or isoquercetin is absorbed after a single dose and evaluate for pharmacokinetic inhibition of protein disulfide isomerase. pharmacodynamic studies will also be performed in an additional cohort of 10 patients with evidence of antiphospholipid antibodies

to compare the absorption and activity of quercetin or isoquercetin with or without ascorbic acid in healthy adults. oral chews containing quercetin (500mg) or isoquercetin(500 mg total) with or without ascorbic acid will be given. pharmacokinetic parameters (auc, cmax, tmax, elimination half-life) will be determined over 24 hours (8 time points). pharmacodynamic inhibition of protein disulfide isomerase activity will also be assessed. in addition to healthy subjects, a cohort of 10 individuals with antiphospholipid antibodies will participate. these participants will receive isoquercetin 1000 mg and have pharmacodynamics studies performed at time 0 and 4 hours. all study drugs will be provided by quercegen pharma.

Eligibility criteria:
inclusion criteria * subject is willing to participate and provide informed consent * subject is considered reliable and capable of adhering to the protocol per the judgment of the investigator * subjects in group d must exhibit good organ reserves (within prior 4 weeks) defined as: 1. estimated gfr \>35 (formula), 2. platelet count \>65 k/ul, 3. hemoglobin \>10.5 grams/dl 4. total bilirubin \<2.0 mg/dl * minimum age 18 years old * body mass index (bmi) between 18 and 35 kg/m2 * for cohort d (antiphospholipid antibodies) a. subjects in group d must have at least one positive antiphospholipid antibody within the last 8 weeks and/or previous confirmed antibodies (2 or more occasions at least 12 weeks apart) : i. positive lupus anticoagulant ii. anticardiolipin antibody igm or igg (\>40u gpl) iii. anti-β2 glycoprotein1 antibody titer (\>35 units) exclusion criteria * pregnant. if female of child-bearing age, negative urinary pregnancy test prior to dosing of quercetin or isoquercetin * no history of malabsorptive gastrointestinal disorder * currently taking aspirin, nsaids, warfarin, low-molecular weight heparin or other anticoagulants (such as direct thrombin inhibitors or factor x inhibitors) a. note: study subjects taking aspirin or nsaids, if treating physician concurs, are permitted to enroll if plan to hold for aspirin 10 days or nsaids 24 hours prior to dosing of quercetin/isoquercetin * prescribed niacin for hyperlipidemia * known hiv * history of sensitivity or intolerance to flavonoids, niacin or ascorbic acid * may not have uncontrolled intercurrent illness including, but not limited to ongoing or active infection, hepatitis, symptomatic congestive heart failure, unstable angina pectoris or cardiac arrhythmia

Keywords: quercetin isoquercetin pharmacokinetic pharmacodynamic
study of msc-exo on the therapy for intensively ill children

Conditions: Sepsis; Critical Illness

Summary: at present, a number of projects related to mscs have been approved for graft-versus-host disease, myocardial infarction, crohn's disease and other diseases, indicating a strong therapeutic potential of mscs. however, the efficacy of msc-exo for severely infected children is not fully evaluated. in our study, patients who met the inclusion criteria will be divided into trial group and control group. clinical and demographic data, as well as treatment outcome will be collected from the electronic health record. this study will evaluate the application and therapeutic effect of msc-exo in severely infected children, and determine the optimal dosage and infusion.

mesenchymal stem cells (mscs) are pluripotent stem cells with high self-renewal ability and multidirectional differentiation potential. studies revealed that local or systemic administration of mesenchymal stem cell-derivrd exosomes (msc-exo) efficiently suppressed detrimental immune response in inflamed tissues and promoted survival and regeneration of injured parenchymal cells. european union countries have written mscs into treatment guidelines for refractory graft-versus-host disease. in china, the technology for isolation, in vitro culture and expansion of mscs is already mature. with further research on the therapeutic efficacy of msc-exo and the development of clinical trials, it is expected to become a treatment for severe illness. a predictable infection plan is going to be widely used in clinics to provide individualized treatment for patients, improve the prognosis of patients and improve the quality of life. the investigators intend to enroll all children who were hospitalized in pediatric intensive care unit picu of children's hospital of fudan university from january 2022 to december 2023. children with a picu length of day less than 48h will be excluded.

Eligibility criteria:
inclusion criteria: * children hospitalized in picu of children's hospital of fudan university exclusion criteria: * discharge within 48 hours * patients without informed consent * incomplete clinical and demographic data

Keywords: sepsis critical illness mesenchymal stem cell derived exosomes
immunologic response to flumist vs. flucelvax

Conditions: Influenza, Human; Immune Response

Summary: the purpose of this study is to evaluate immunologic response to different types of influenza vaccine among children/adolescents/young adults 4-21 years of age. this is a randomized controlled trial (rct), that will assess immune response in about 440 participants (about 220 per vaccine arm) pre- and post-vaccination to flumist (live attenuated influenza vaccine given by nasal administration) and flucelvax (egg-free cell-culture inactivated influenza vaccine).

this is a non-blinded, randomized controlled trial analyzing influenza vaccine immunogenicity response in children/adolescents/young adults aged 4-21 years given one of two fda approved and licensed influenza vaccines: flumist (live attenuated influenza vaccine by nasal administration) and flucelvax (egg-free cell-culture inactivated influenza vaccine). this study will enroll about 440 healthy participants, about 220 per vaccine arm. participants will be randomized in blocks of 4 using a 1:1 allocation to receive either flumist or flucelvax. blood work will be conducted on all participants at baseline prior to vaccine receipt and post-vaccination at day 7 (range 6-9 days) and day 28 (range 21-35 days). the primary objective of the study is to determine pre- and post-serologic responses to each vaccine type.

Eligibility criteria:
inclusion criteria: * aged 4-21 years; * has prior vaccination history available (which can be determined based either on medical record review or through state registry review); * plans to receive the current seasonal influenza vaccination at one of the recruiting sites exclusion criteria: * unable or unwilling to completed required study activities, including informed consent, randomization to vaccine, and bloodwork; * has already received influenza vaccine for the current season; * has a known immunocompromising condition or is on an immunosuppressing medication (e.g., high dose steroids \>10 days); * is known to be pregnant; * has a history of severe allergy to eggs or to influenza vaccine or any of its components
prevelance of uterine vein and uterine vein system variations

Conditions: Uterine Vein Injury Left; Uterine Vein Injury Right

Summary: contrary to the uterine arterial system, our knowledge about superficial and deep uterine vein prevalence and anatomic variations are limited. the present study aims to deepen and clarify our knowledge on superficial and deep uterine vein anatomy, prevalence and relationship with other neighbouring structures which may be helpful in uterine transplantation and radical hysterectomy operations.

despite that two veins draining the uterus, superficial and deep, are described, their true anatomy, number, calibers, trajectories, relationships with sympathetic and parasympathetic nerves and internal iliac vasculature and ureters are quite limited. additionally, variations of these vasculature are much less described. the aim of this study is to increase the our current knowledge about these anatomical information and also to calculate the prevalence of superficial and deep uterine veins which may potentially decrease the possible complications such as bleeding in uterine transplantation surgery and nerve sparing radical hysterectomy for cervical cancer.

Eligibility criteria:
inclusion criteria: endometrium and cervical cancer patients that will be operated - exclusion criteria: any women in whom uterine vascular anatomy that might be changed for a specific disease such as myomas, uterine infections, etc. -
the effect of high tone power therapy on fatigue and functional outcomes in multiple sclerosis

Conditions: Multiple Sclerosis

Summary: to investigate the effect of "high tone power therapy" (htpt) on fatigue and functional outcomes in multiple sclerosis (ms). background: fatigue and functional limitations considered serious disorders in patients with multiple sclerosis that lead to impairment of the physical activities and disruption of the quality of life (qol). hypotheses: this study hypothesized that: high tone power therapy will have a significant beneficial effect on fatigue and functional outcomes in in multiple sclerosis research question: is there a beneficial effect of high tone power therapy on fatigue and functional outcomes in multiple sclerosis?

double blind randomized study including 40 patients with ms. the patients will be randomly allocated into 2 arms: active arm and placebo arm; in the active arm patients will receive "high tone power therapy" in addition to the physical therapy conventional selected exercise program, and the placebo arm will receive the same physical exercise program with sham "high tone power therapy". either program will be applied 3 times per week for 4 weeks. the evaluation methods will be done using: * expanded disability status scale (edss) / functional systems score (fss), * fatigue severity scale and modified fatigue impact scale. before the exercise program and after finishing the exercise program, the assessor of the patients, before and after the program, will be blinded to the technique used (whether active or sham).

Eligibility criteria:
inclusion criteria: - both genders * age from 18-50 years * all ms types will be included (relapsing remitting "rr", secondary progressive "sp, and primary progressive "pp") * patients with residual motor / cerebellar / sphincteric impairment that are not responding to conventional pharmacological treatments. * at least 6 months after the last relapse. * edss from 2-6.5. * all patients should be receiving a disease modifying therapy with stabilization of the disease course for 1 year in case of spms and ppms. * patients that can pay regular visits to the physical center without potential interruption. * patients who agree to participate and sign the informed consent. - body mass index (20:29) kg/m2 exclusion criteria: * cognitive impairment that can hinder the ability to communicate or to understand program instructions. * neurological deficits due to any disease other than ms * orthopedic abnormalities, * secondary musculoskeletal complication. * patients who refuse participation or signing the informed consent.

Keywords: high tone power therapy fatigue functional outcomes
biomarkers in blood samples from patients with stage iv melanoma previously treated with sargramostim

Conditions: Melanoma (Skin)

Summary: rationale: studying samples of blood from patients treated with sargramostim in the laboratory may help doctors learn more about the effects of sargramostim on cells. it may also help doctors understand how patients respond to treatment. purpose: this research trial studies biomarkers in blood samples from patients with stage iv melanoma previously treated with sargramostim.

objectives: primary * to correlate circulating myeloid-derived suppressor cells (mdsc) and treg frequencies with clinical outcome. secondary * to correlate circulating anti-sargramostim (gm-csf) antibody levels with clinical outcome. outline: archived peripheral blood mononuclear cells and serum samples are analyzed for circulating myeloid-derived suppressor cells, treg (cd3+/cd4+/cd25hi/foxp3+) frequency, and anti-sargramostim (anti-gm-csf) antibody levels by flow cytometry and anti-gm-csf neutralizing antibody assay.

Eligibility criteria:
disease characteristics: * diagnosed with melanoma * stage iv disease * hla-a2\^+ and a2\^+ * received sargramostim on clinical trial ecog-4697 * specimens collected at baseline and either day 43 or day 85 (based on most consistent availability) from long-term survivors and patients with poor survival patient characteristics: * not specified prior concurrent therapy: * see disease characteristics

Keywords: stage iv melanoma
68ga-ny104 pet/ct guided radiation therapy in ccrcc.

Conditions: Clear Cell Renal Cell Carcinoma

Summary: radiation therapy (rt) is an effective treatment for patients with advanced-stage clear cell renal cell carcinoma (ccrcc). current evidence has shown promising outcomes combining radiation therapy and standard systemic therapy in patients with metastatic/recurrent ccrcc. caix is a highly sensitive and specific biomarker expressed on ccrcc and in previous studies the investigators have shown excellent diagnostic efficacy of 68ga-ny104, a caix-targeted pet tracer, in patients with metastatic ccrcc. in this study, the investigators aim to investigate the effect of 68ga-ny104, and 18f-fdg pet/ct guided rt combining standard systemic therapy in patients with metastatic ccrcc.


Eligibility criteria:
inclusion criteria: * age ≥ 18 years old * histologically or cytologically confirmed clear cell renal cell carcinoma * eligible for radiation therapy: no more than 10 lesions in total * expected survival: over 3 months * ecog: 0 or 1 * sufficient organ function * written informed consent exclusion criteria: * brain metastasis/carcinomatous meningitis * other malignant tumors that are not controlled within 5 years, except for non-metastatic low-risk prostate cancer. * pregnant or breastfeeding. * active infection.

Keywords: clear cell renal cell carcinoma caix radiation therapy 68ga-ny104
interprofessional management of chronic back pain in rural and remote setting: use of telehealth vs. secure laptop-based videoconferencing

Conditions: Back Pain Lower Back Chronic

Summary: this pilot study will evaluate the impact and overall experience of an interprofessional chronic low back pain patient care approach for people in rural and remote areas using telehealth technology compared to secure laptop based videoconferencing (vidyo).

people with chronic low back pain will be recruited to participate in a team assessment with a local rural nurse practitioner and an-urban based physiotherapist linking through telehealth. the assessment will include a detailed history, physical examination and jointly-delivered education and recommendations for further community-based management. pre and post measures of self-reported pain, back-specific function, quality of life, and satisfaction will be completed 2-4 weeks after the assessment. comparison of short-term outcomes will be made with a group of participants from another study using the a different telehealth technology (secure laptop based videoconferencing) same inclusion criteria, measures and health care providers (clin trials.gov nct02225535). the health care providers will be interviewed to get feedback on their preference and experience using the different type of telehealth technology.

Eligibility criteria:
inclusion criteria: chronic low back pain localized below costal margins and above gluteal folds and/or related leg pain, which is bad enough to limit their usual activities or daily routine and has been present for at least 3 months exclusion criteria: * people with: third party payer insurance (i.e.worker's compensation board) for their back related complaints, with primarily neck or thoracic pain, and/ or with language, reading or comprehension barriers that would limit their ability to adequately complete the required study paperwork will be excluded from participating in the study.

Keywords: rural health telehealth physiotherapy interprofessional
safety and efficacy of 333369 in the treatment of partial epilepsy

Conditions: Refractory Epilepsy

Summary: the primary objective of this study is to evaluate the efficacy, safety, and tolerability of 4 daily doses of rwj-333369 as adjunctive treatment of refractory partial epilepsy in subjects who are between 18 and 70 years of age, inclusive


Eligibility criteria:
inclusion criteria: 1. age 18-70 years old, 2. diagnosis of epilepsy for at least 1 year, 3. presenting, on average, at least 3 partial onset seizures per month, 4. currently treated with a stable dose (i.e., for at least 4 weeks) of no more than 3 anti-epileptic drugs (aeds), exclusion criteria: 1. have experienced status epilepticus in the past 3 months, 2. have any serious diseases, 3. history of major psychiatric disorders within the past 2 years. 4. have received an experimental drug/device within the past 30 days 5. are pregnant or breastfeeding.
comparison of minimal fresh gas requirements of baby ear and jackson rees anesthetic circuit

Conditions: Anesthesia

Summary: the investigators invented the baby enclosed afferent reservoir anesthesia circuit (baby ear) which could be used safely in children between 5 and 20 kg, using a fresh gas flow of 2.5 and 3 l/min in the spontaneous breathing and controlled breathing, respectively. there has as yet been no study comparing the minimal fresh gas flow between the baby ear and jackson-rees anesthesia circuit (jr).

after intubation, a caudal block with 0.25% bupivacaine with adrenaline :200,000 0.5 to 1 ml/kg was done. anesthesia was maintained with a 50% n2o/o2 combination with sevoflurane 1 to 3%, adjusted to ensure a proper anesthetic level to achieve normal vital signs and to keep the end-tidal co2 (etco2) \<60 mmhg. fentanyl 1 μg/kg/h was infused during the procedure. all patients were pontaneously ventilated with fgf 500 ml/kg/min at the start of each anesthesia breathing circuit, waiting for the depth of anesthesia to be maintained and the patient to spontaneously breathe for at least 10 minutes. baseline etco2 and imco2 were then measured. the pulse rate, blood pressure and respiratory rate were recorded every five minutes. the fgf was reduced by 50 ml/kg/min every five minutes, waiting for the imco2 to be regularly maintained at least 60 sec. the etco2 and imco2 values were recorded until rebreathing occurred (imco2 \>2 mmhg) and measurements continued until rebreathing was not clinically acceptable (imco2 \>6 mmhg). the minimal fgf before rebreathing occurred (fgf of imco2 ≤2 mmhg) is the amount of gas that does not cause rebreathing. the minimal fgf for which rebreathing was still acceptable (fgf of imco2 ≤6 mmhg) is the amount of gas that was clinically acceptable. after switching the anesthesia breathing circuit, the fgf was increased to 500 ml/kg/min for 10 minutes and the procedure was repeated. the minimal fgf before the rebreathing occurred and the fgf at hich rebreathing was still clinically acceptable were recorded. after extubation, all of the patients were observed in the pacu and relevant factors recorded until there was good recovery from anesthesia before sending the patient back to the ward.

Eligibility criteria:
inclusion criteria: * weight between 5 and 20 kg * asa physical status i or ii * scheduled for general anesthesia exclusion criteria: * has respiratory or cardiovascular disease * can not breathe spontaneously during anesthesia * for whom the caudal block can not be done

Keywords: enclosed afferent reservoir jackson rees system anesthesia breathing circuit spontaneous breathing pediatric anesthesia
bascom cleft lift versus limberg flap for sacrococcygeal pilonidal sinus

Conditions: Pilonidal Sinus

Summary: a pilonidal sinus is a cyst on the natal cleft of the buttocks that often contains hair and skin debris. the condition is common and requires surgery to be cured. several surgical procedures are described in literature. limberg flap technique is frequently used technique for this disease all over the world. however, bascom cleft lift technique is relatively newer technique. the purpose of this prospective randomized study is comparison of these techniques about patient satisfaction for postoperative period.


Eligibility criteria:
inclusion criteria: * all types of pilonidal sinus or cyst * the patient understands trial information and is capable of making a decision for informed consent after having received information. * the patient wants to undergo surgery for pilonidal sinus and accepts participation in the trial. exclusion criteria: * acute abscess formation (cruse-foord class iv) * patient with minor inflammation are included to trial after two-week antibiotic treatment (cruse-foord class iii)

Keywords: bascom procedure, limberg, pilonidal disease